Cannabinoids is a “No-Go” While a Cancer Patient is on Immunotherapy; but is It Safe to Use Psychedelics During Cancer Immunotherapy?
bioRxiv (Cold Spring Harbor Laboratory) February 2, 2021 E. Amit Romach, M. Nachliely, Olivia Moran et al. 2 citations preprint
Psychedelics such as LSD and psilocybin, increasingly used by cancer patients to relieve anxiety and depression, may interfere with immune-based cancer treatments like immune checkpoint inhibitors. Preclinical data suggest that consuming psychedelics during such therapy could negatively impact tumor growth and diminish the therapeutic benefits of immune checkpoint inhibitors. The authors call for further research to validate these findings, given the rising use of cannabinoids and psychedelics among cancer patients receiving immune-based treatments.